At the same time, neither the use of mortality inhibitors nor ferroptosis related-inhibitors can completely eliminate the effect of ART, indicating that ART has a combined inhibitory effect on ovarian cancer tumor cells in a variety of ways (86).Octreotide, an FDA-approved medication that is commonly used in the clinical treatment of ovarian cancer, can directly decrease the expression of GPX4 inducing ferroptosis (87). This evidence concerns the gene GPX4 and ovarian carcinoma.